Celularity Inc (CELU)
NASDAQHealth CareBiotechnologySnapshot 2026-11-05
$0.73-10.32%
Close 2026-11-05 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-11-05
QuarterlyIQ Insights · CELU
How strong the business is — where it ranks within its sector on capital efficiency and cash generation, and how well management has been executing.
How management runs the business: capital, margins, balance sheet, and how reliably they guide and deliver.
A guidance track record builds as the company issues and delivers on guidance.
Priorities management has stated in recent disclosures, with status and evidence drawn from earnings calls, filings, and press releases.
As such, our collaboration with Vesalius represents an important business opportunity for Celularity and a practical extension of our regenerative longevity strategy.”
Stated in a supplied disclosure. Management reported: “As such, our collaboration with Vesalius represents an important business opportunity for Celularity and a practical extension of our regenerative longevity strategy.”” “Since making cenplacel-L available to qualified physicians for investigational use in such jurisdictions, Celularity believes this early commercial traction supports the Company’s decision to strengthen its commercial leadership with the appointment of Mr. Gonzalez and the continued build-out of commercial capabilities designed to support appropriate physician engagement, education and market development.” Revenue was $5.432 million in 2026-Q2.
Each factor is a parallel diagnostic with a clear read of what it shows and how names like it have historically fared. Never aggregated into a single score.
Operating income rose in 2 of the last 3 quarter-over-quarter moves. Historically, Health Care names rated neutral grew net income 51% of the time over the next year (vs 41% for the rest of the cohort, n=13498).
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Barach. “We have made meaningful progress strengthening Celularity’s capital structure and operating profile.
Stated in 1 of 1 supplied quarters. Management reported: “Barach. “We have made meaningful progress strengthening Celularity’s capital structure and operating profile.” “Diamandis, M.D., and Mr. Barach, who recently joined the Board as part of Celularity’s broader recapitalization and strategic repositioning.” Operating income was $-4.237 million in 2026-Q2.
“Barach. “We have made meaningful progress strengthening Celularity’s capital structure and operating profile.”
“Rick’s appointment comes at an important time for Celularity as we continue to advance our revenue-generating strategy and expand the reach of our regenerative medicine platform,” said Robert J.
Stated in a supplied disclosure. Management reported: “Since making cenplacel-L available to qualified physicians for investigational use in such jurisdictions, Celularity believes this early commercial traction supports the Company’s decision to strengthen its commercial leadership with the appointment of Mr. Gonzalez and the continued build-out of commercial capabilities designed to support appropriate physician engagement, education and market development.” “Mr. Gonzalez will also lead expansion of Celularity’s Lifebank product offering for expectant parents and adults who wish to bank their own cells for potential future use.”
Build commercial reach for cenplacel-L and Lifebank through physician engagement, responsible access and broader consumer awareness.
Monetize non-core biomaterials assets and concentrate resources on cellular therapeutics, the longevity strategy and scalable manufacturing.
Over the trailing year it converted 0.33x of net income into operating cash flow.
Not enough signal yet.
Not enough signal to read sensitivity to the broad stock market, the US dollar, long-term interest rates, real (inflation-adjusted) rates, Fed net liquidity (low R² over the window).
46 material management or governance events in the past 24 months, led by capital-allocation actions. Historically, Health Care names rated volatile grew net income 45% of the time over the next year (vs 45% for the rest of the cohort, n=10076).
Not investment advice. As of 2026-11-05.